Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FAST trial clears febuxostat of increased mortality in gout

Key clinical point: Febuxostat demonstrated noninferiority to allopurinol for mortality.

Major finding: Unlike the CARES trial in the United States, the FAST trial suggested no increased mortality risk associated with febuxostat.

Study details: Multicenter, prospective, randomized study of 6,128 people.

Disclosures: Menarini, Ipsen, and Teijin Pharma funded the study. The University of Dundee receives research funds from Menarini. Dr. MacDonald disclosed that he received speaker or consultant fees from Menarini.


MacDonald T et al. Arthritis Rheumatol. 2020;72(suppl 10). ACR 2020, Abstract L08.